Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome

Completed · Phase 1

Conditions studied: Myelodysplastic Syndrome

In brief

This is a multicenter, open-label, Phase 1 study to assess the safety and antitumor activity of MEDI4736 as Monotherapy or in Combination with Tremelimumab with or without Azacitidine in Subjects with myelodysplastic syndrome after treatment with hypomethylating agents

Key facts

Study ID

NCT02117219

Run by

MedImmune LLC

People needed

67

Starts

2014-05-20

Expected to finish

2019-04-30

Last updated by the study team

2019-05-10

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult male or female subjects with pathologically confirmed MDS who failed to respond, relapsed after an initial response, or were unable to tolerate hypomethylating agents, ECOG performance status of 0 - 2, and adequate organ and marrow function.

You may not qualify if…

• Concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment, prior MAb against CTLA-4, PD-1, or PD-L1, alllogenic or haploidentical transplant, current immunosuppressive medication or autoimmune or inflammatory disease.

Where it is running

• Research Site — Scottsdale, Arizona, United States
• Research Site — Los Angeles, California, United States
• Research Site — New Haven, Connecticut, United States
• Research Site — Tampa, Florida, United States
• Research Site — Atlanta, Georgia, United States
• Research Site — Chicago, Illinois, United States
• Research Site — Baltimore, Maryland, United States
• Research Site — Boston, Massachusetts, United States
• Research Site — Detroit, Michigan, United States
• Research Site — Rochester, Minnesota, United States
• Research Site — New York, New York, United States
• Research Site — New York, New York, United States
• Research Site — Greenville, South Carolina, United States
• Research Site — Houston, Texas, United States
• Research Site — San Antonio, Texas, United States
• Research Site — Milwaukee, Wisconsin, United States
• Research Site — Paris, France
• Research Site — Dresden, Germany
• Research Site — Brighton, United Kingdom
• Research Site — London, United Kingdom
• Research Site — Manchester, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.